Abstract
It is suspected that ERCC5 rs1047768 and rs17655 polymorphisms influence the response to platinum-based chemotherapy. This meta-analysis was performed to summarize the scattered evidence regarding the association between these two polymorphisms and sensitivity to platinum-based treatment. Thirteen studies were included after a comprehensive literature search. The pooled odds ratios and 95% confidence intervals suggested that the C allele of the ERCC5 rs1047768 polymorphism is associated with elevated sensitivity to platinating agents, especially for Chinese patients. However, no difference among rs17655 genotypes could be detected.
Highlights
Platinum-based chemotherapies are regarded as the most efficacious cancer treatment option
It is suspected that ERCC5 rs1047768 and rs17655 polymorphisms influence the response to platinum-based chemotherapy
Our meta-analysis examined the influence of the ERCC5 rs1047768 and rs17655 polymorphisms on the sensitivity to platinum-based chemotherapy in cancers
Summary
Platinum-based chemotherapies are regarded as the most efficacious cancer treatment option. Platinum-based chemotherapy exerts its antitumor effect by suppressing DNA replication through the formation of platinum-DNA adducts, which would be recognized and remedied by cellular DNA repair mechanisms [2,3,4] Genetic variation of those DNA repair systems could be one of the indicators of sensitivity to platinum-based chemotherapy [5,6,7]. The amino-acid substitution caused www.impactjournals.com/oncotarget by this polymorphism may lead to differential interacting affinities, and impact NER efficiency [14]. The effect of these two ERCC5 polymorphisms on the efficacy of platinum-based chemotherapy should be quantitatively evaluated
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
